Essential Pharma Archives | Be Korea-savvy

Home / Posts tagged Essential Pharma

Essential Pharma announces €900 million recapitalisation through a Gyrus Capital Continuation Vehicle led by AlpInvest and new strategic financing from Sixth Street

Provides significant resources to build on diversified portfolio of established and rare disease medicines Egham, UK – 12 December 2024 – Essential Pharma (“Essential” or “the Company”), an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, today announces the completion of [...]

Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules

Reminyl® is an established CNS brand for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type The acquisition ensures continued access to this essential cholinesterase inhibitor for dementia patients in key markets Significant addition to Essential Pharma’s portfolio of specialty central nervous system (CNS) medicines and further expands the company’s presence [...]

Essential Pharma Acquires Renaissance Pharma Ltd with Its Clinical Stage Immunotherapy for the Treatment of Hhigh-risk Neuroblastoma

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma portfolio and second product within rare disease Egham, UK – 9 April 2024 (Korea Bizwire) – Essential Pharma, an international specialty pharma group focused on ensuring that patients have [...]

Essential Pharma and AcedrA Biopharmaceuticals Sign Distribution Agreement to Commercialize Essential Medicines in the Middle East and North Africa Region

ZUG, Switzerland and EGHAM, United Kingdom and RIYADH, Saudi Arabia, March 26, 2024 (Korea Bizwire) – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has signed a Distribution Agreement with AcedrA BioPharmaceuticals (“AcedrA”), a [...]

Essential Pharma Acquires European Rights to Colobreathe®(colistimethate sodium) from Teva

Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients The acquisition will help ensure continued access to an important medicine for this vulnerable patient population First rare disease medicine to be added to the Essential Pharma product portfolio [...]

UK Marketing Authorisations for IOPIDINE® (Apraclonidine) Fully Transferred to Essential Pharma as Change in UK NICE Guidelines for Glaucoma Treatment Expected to Lead to Increase in Patients’ Need for Product

Zug, Switzerland & Egham, UK, Dec. 15 (Korea Bizwire) – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has completed the transfer of the UK marketing authorisations for IOPIDINE® (apraclonidine) in both available concentrations, IOPIDINE® 0.5% and [...]

Essential Pharma Announces the Acquisition of HALDOL®

Zug, Switzerland, Dec. 7 (Korea Bizwire) – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of HALDOL® (haloperidol) and HALDOL® Decanoate (haloperidol decanoate) from Janssen Pharmaceutica NV. HALDOL® is a first-generation [...]